Authors:
STAHL M
VANHOEFER U
STUSCHKE M
WALZ MK
MULLER C
WILKE H
Citation: M. Stahl et al., PREOPERATIVE SEQUENTIAL CHEMOTHERAPY AND RADIOCHEMOTHERAPY IN LOCALLYADVANCED CARCINOMAS OF THE LOWER ESOPHAGUS AND GASTROESOPHAGEAL JUNCTION, European journal of cancer, 34(5), 1998, pp. 668-673
Authors:
HARSTRICK A
GONZALES A
SCHLEUCHER N
VANHOEFER U
LU K
FORMENTO JL
MILANO G
WILKE H
SEEBER S
RUSTUM Y
Citation: A. Harstrick et al., COMPARISON BETWEEN SHORT OR LONG EXPOSURE TO 5-FLUOROURACIL IN HUMAN GASTRIC AND COLON-CANCER CELL-LINES - BIOCHEMICAL-MECHANISM OF RESISTANCE, Anti-cancer drugs, 9(7), 1998, pp. 625-634
Authors:
HARSTRICK A
MAYER S
HILGER R
MULLER C
DOHMEN D
KLOPPEL R
VANHOEFER U
SCHEULEN ME
WILKE H
SEEBER S
Citation: A. Harstrick et al., COMBINATION THERAPY WITH INFUSIONAL 5-FU AND TOMUDEX FOR PATIENTS (PTS) WITH ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY, Annals of oncology, 9, 1998, pp. 170-170
Authors:
WILKE H
VANHOEFER U
HARSTRICK A
ACHTERRATH W
PREUSSER P
CLEMENS MR
THIEL E
FLASSHOVE M
FINK U
SEEBER S
Citation: H. Wilke et al., PHASE-II STUDY OF DOCETAXEL (D) AS SALVAGE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC-CANCER, Annals of oncology, 9, 1998, pp. 246-246
Authors:
VANHOEFER U
HAPKE G
HARSTRICK A
ACHTERRATH W
RUSTUM YM
SEEBER S
Citation: U. Vanhoefer et al., SCHEDULE-DEPENDENT ANTITUMOR EFFICACY OF IRINOTECAN (CPT-11) AND 5-FLUOROURACIL (5-FU) IN NUDE-MICE BEARING COLON-TUMOR XENOGRAFTS THAT ARERESISTANT TO 5-FU, Annals of oncology, 9, 1998, pp. 634-634
Citation: A. Harstrick et al., NEW DRUGS IN COLORECTAL-CANCER - A REVIEW OF ANTITUMOR-ACTIVITY AND CROSS-RESISTANCE PATTERNS OF TOPOISOMERASE-I INHIBITORS, THYMIDYLATE SYNTHETASE INHIBITORS, AND OXALIPLATIN, Onkologie, 21(2), 1998, pp. 95-103
Authors:
YIN MB
GUO B
VOIGT W
VANHOEFER U
GIBBS JF
SKENDERIS BS
FRANK C
WRZOSEK C
RUSTUM YM
Citation: Mb. Yin et al., NOVEL CELLULAR DETERMINANTS FOR REVERSAL OF MULTIDRUG-RESISTANCE IN CELLS EXPRESSING P170-GLYCOPROTEIN, Biochimica et biophysica acta. Molecular cell research, 1401(3), 1998, pp. 265-276
Authors:
VANHOEFER U
VOIGT W
HILGER RA
YIN MB
HARSTRICK A
SEEBER S
RUSTUM YM
Citation: U. Vanhoefer et al., CELLULAR DETERMINANTS OF RESISTANCE TO INDOLOCARBAZOLE ANALOG LO[2,3-ALPHA]PYRROLO[3,4-C]CARBAZOLE-5,7(6H)-DIONE (NB-506), A NOVEL POTENT TOPOISOMERASE-I INHIBITOR, IN MULTIDRUG-RESISTANT HUMAN TUMOR-CELLS, Oncology research, 9(9), 1997, pp. 485-494
Authors:
HARSTRICK A
VANHOEFER U
HEIDEMANN A
DRUYEN H
WILKE H
SEEBER S
Citation: A. Harstrick et al., DRUG-INTERACTIONS OF 5-FLUOROURACIL WITH EITHER CISPLATIN OR LOBAPLATIN - A NEW, CLINICALLY ACTIVE PLATINUM ANALOG IN ESTABLISHED HUMAN CANCER CELL-LINES, Anti-cancer drugs, 8(4), 1997, pp. 391-395
Authors:
VANHOEFER U
CAO S
HARSTRICK A
SEEBER S
RUSTUM YM
Citation: U. Vanhoefer et al., COMPARATIVE ANTITUMOR EFFICACY OF DOCETAXEL AND PACLITAXEL IN NUDE-MICE BEARING HUMAN TUMOR XENOGRAFTS THAT OVEREXPRESS THE MULTIDRUG-RESISTANCE PROTEIN (MRP), Annals of oncology, 8(12), 1997, pp. 1221-1228
Authors:
RUSTUM YM
HARSTRICK A
CAO SS
VANHOEFER U
YIN MB
WILKE H
SEEBER S
Citation: Ym. Rustum et al., THYMIDYLATE SYNTHASE INHIBITORS IN CANCER-THERAPY - DIRECT AND INDIRECT INHIBITORS, Journal of clinical oncology, 15(1), 1997, pp. 389-400
Authors:
VOIGT W
VANHOEFER U
YIN MB
MINDERMAN H
SCHMOLL HJ
RUSTUM YM
Citation: W. Voigt et al., EVALUATION OF TOPOISOMERASE-I CATALYTIC ACTIVITY AS DETERMINANT OF DRUG RESPONSE IN HUMAN CANCER CELL-LINES, Anticancer research, 17(5A), 1997, pp. 3707-3711
Authors:
YIN MB
VOIGT W
PANADERO A
VANHOEFER U
FRANK C
PAJOVIC S
AZIZKHAN J
RUSTUM YM
Citation: Mb. Yin et al., P53 AND WAF1 ARE INDUCED AND RB PROTEIN IS HYPOPHOSPHORYLATED DURING CELL-GROWTH INHIBITION BY THE THYMIDYLATE SYNTHASE INHIBITOR ZD1694 (TOMUDEX), Molecular pharmacology, 51(4), 1997, pp. 630-636
Authors:
VANHOEFER U
YIN MB
HARSTRICK A
SEEBER S
RUSTUM YM
Citation: U. Vanhoefer et al., CARBAMOYLATION OF GLUTATHIONE-REDUCTASE BY N,N-BIS(2-CHLOROETHYL)-N-NITROSOUREA ASSOCIATED WITH INHIBITION OF MULTIDRUG-RESISTANCE PROTEIN (MRP) FUNCTION, Biochemical pharmacology, 53(6), 1997, pp. 801-809
Authors:
VANHOEFER U
CAO SR
MINDERMAN H
TOTH K
SCHEPER RJ
SLOVAK ML
RUSTUM YM
Citation: U. Vanhoefer et al., PAK-104P, A PYRIDINE ANALOG, REVERSES PACLITAXEL AND DOXORUBICIN RESISTANCE IN CELL-LINES AND NUDE-MICE BEARING XENOGRAFTS THAT OVEREXPRESSTHE MULTIDRUG-RESISTANCE PROTEIN, Clinical cancer research, 2(2), 1996, pp. 369-377
Authors:
VANHOEFER U
CAO SS
MINDERMAN H
TOTH K
SKENDERIS BS
SLOVAK ML
RUSTUM YM
Citation: U. Vanhoefer et al., D,L-BUTHIONINE-(S,R)-SULFOXIMINE POTENTIATES IN-VIVO THE THERAPEUTIC EFFICACY OF DOXORUBICIN AGAINST MULTIDRUG-RESISTANCE PROTEIN-EXPRESSING TUMORS, Clinical cancer research, 2(12), 1996, pp. 1961-1968
Authors:
WILKE H
KLAASSEN U
ACHTERRATH W
LOSCH M
VANHOEFER U
HAYUNGS J
HARSTRICK A
STAHL M
EBERHARDT W
BECHER R
SEEBER S
Citation: H. Wilke et al., PHASE I II STUDY WITH A WEEKLY 24-HOUR INFUSION OF 5-FLUOROURACIL PLUS HIGH-DOSE FOLINIC ACID (HD-FU/FA) IN INTENSIVELY PRETREATED PATIENTSWITH METASTATIC BREAST-CANCER/, Annals of oncology, 7(1), 1996, pp. 55-58
Authors:
VANHOEFER U
PREUSSER P
STAHL M
HARSTRICK A
SEEBER S
WILKE H
Citation: U. Vanhoefer et al., PHASE-II STUDY OF A SEQUENTIAL SCHEDULE OF ETOPOSIDE, FOLINIC ACID, 5-FLUOROURACIL, AND CISPLATIN (ELF-P) IN PATIENTS WITH ADVANCED GASTRIC-CANCER, Tumordiagnostik & Therapie, 17(6), 1996, pp. 188-190
Authors:
STAHL M
VANHOEFER U
FINK U
KORN M
EIGLER FW
SIEWERT JR
SEEBER S
WILKE H
Citation: M. Stahl et al., PHASE-II STUDY OF WEEKLY HIGH-DOSE 5-FLUOROURACIL AND FOLINIC ACID PLUS BIWEEKLY ALTERNATING CISPLATIN AND EPIRUBICIN (FUFACE) IN PATIENTS WITH ADVANCED GASTRIC-CARCINOMA, Onkologie, 19(5), 1996, pp. 416-418
Authors:
MINDERMAN H
VANHOEFER U
TOTH K
YIN MB
MINDERMAN MD
WRZOSEK C
SLOVAK ML
RUSTUM YM
Citation: H. Minderman et al., DIOC(2)(3) IS NOT A SUBSTRATE FOR MULTIDRUG-RESISTANCE PROTEIN (MRP)-MEDIATED DRUG EFFLUX, Cytometry, 25(1), 1996, pp. 14-20
Authors:
MINDERMAN H
VANHOEFER U
TOTH K
MINDERMAN MD
RUSTUM YM
Citation: H. Minderman et al., A UNIQUE HUMAN OVARIAN-CARCINOMA CELL-LINE EXPRESSING CD34 IN ASSOCIATION WITH SELECTION FOR MULTIDRUG-RESISTANCE, Cancer, 78(11), 1996, pp. 2427-2436
Authors:
KLAASSEN U
HARSTRICK A
SCHLEUCHER N
VANHOEFER U
SCHRODER J
WILKE H
SEEBER S
Citation: U. Klaassen et al., ACTIVITY-DEPENDENT AND SCHEDULE-DEPENDENT INTERACTIONS OF PACLITAXEL,ETOPOSIDE AND HYDROPEROXY-IFOSFAMIDE IN CISPLATIN-SENSITIVE AND CISPLATIN-REFRACTORY HUMAN OVARIAN-CARCINOMA CELL-LINES, British Journal of Cancer, 74(2), 1996, pp. 224-228
Authors:
VANHOEFER U
HARSTRICK A
WILKE H
SCHLEUCHER N
WALLES H
SCHRODER J
SEEBER S
Citation: U. Vanhoefer et al., SCHEDULE-DEPENDENT ANTAGONISM OF PACLITAXEL AND CISPLATIN IN HUMAN GASTRIC AND OVARIAN-CARCINOMA CELL-LINES IN-VITRO, European journal of cancer, 31A(1), 1995, pp. 92-97
Authors:
HARSTRICK A
VANHOEFER U
SCHLEUCHER N
SCHROEDER J
BAUMGART J
SCHEULEN ME
WILKE H
SEEBER S
Citation: A. Harstrick et al., ACTIVITY OF N-BENZYL-ADRIAMYCIN-14-VALERATE (AD198), A NEW ANTHRACYCLINE DERIVATE, IN MULTIDRUG-RESISTANT HUMAN OVARIAN AND BREAST-CARCINOMA CELL-LINES, Anti-cancer drugs, 6(5), 1995, pp. 681-685